Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 2 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - adults,wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial body mass index (bmi) of,? ?30 kg/m2 (obesity), or,? ?27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see section 5.1 pharmacodynamic properties ? clinical trials).,adolescents,wegovy? is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,? obesity* and,? body weight above 60 kg,treatment with wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their bmi by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*obesity (bmi ? 95th percentile) as defined on sex- and age-specific bmi growth charts (cdc.gov) (see table 1).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 14 mg - tablet - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; salcaprozate sodium - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. ? as monotherapy if metformin is considered inappropriate due to intolerance or contraindications; or ? in combination with other medicinal products for the treatment of type 2 diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 1.34 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; phenol; sodium hydroxide; propylene glycol; water for injections; hydrochloric acid - ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:,- as monotherapy when metformin is not tolerated or contraindicated.,- in addition to other medicinal products for the treatment of type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 1.34 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; phenol; sodium hydroxide; propylene glycol; water for injections; hydrochloric acid - ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:,- as monotherapy when metformin is not tolerated or contraindicated.,- in addition to other medicinal products for the treatment of type 2 diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 1 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - adults,wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial body mass index (bmi) of,? ?30 kg/m2 (obesity), or,? ?27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see section 5.1 pharmacodynamic properties ? clinical trials).,adolescents,wegovy? is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,? obesity* and,? body weight above 60 kg,treatment with wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their bmi by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*obesity (bmi ? 95th percentile) as defined on sex- and age-specific bmi growth charts (cdc.gov) (see table 1).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - semaglutide, quantity: 0.5 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - adults,wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial body mass index (bmi) of,? ?30 kg/m2 (obesity), or,? ?27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity (see section 5.1 pharmacodynamic properties ? clinical trials).,adolescents,wegovy? is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with initial:,? obesity* and,? body weight above 60 kg,treatment with wegovy should be re-evaluated and discontinued if adolescent patients have not reduced their bmi by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.,*obesity (bmi ? 95th percentile) as defined on sex- and age-specific bmi growth charts (cdc.gov) (see table 1).

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - semaglutide - injection, solution - semaglutide 0.25mg/0.5ml

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - semaglutide - injection, solution - semaglutide 0.5mg/0.5ml

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - semaglutide - injection, solution - semaglutide 1.7mg/ 0.75ml

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - semaglutide - injection, solution - semaglutide 1.0mg/0.5ml